FDA Approves Novo Nordisk’s Rybelsus Diabetes Pill to Reduce Heart Risk
The drug, called Rybelsus, is the only oral GLP-1 medication available. It was previously approved to treat Type 2 diabetes but under the new approval, Novo Nordisk can now market the drug’s benefits of reducing cardiovascular events.
Source link
About The Author
